1. Home
  2. GSM vs ZYME Comparison

GSM vs ZYME Comparison

Compare GSM & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ferroglobe PLC

GSM

Ferroglobe PLC

HOLD

Current Price

$4.62

Market Cap

782.0M

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$25.70

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSM
ZYME
Founded
2015
2003
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
782.0M
2.0B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
GSM
ZYME
Price
$4.62
$25.70
Analyst Decision
Buy
Strong Buy
Analyst Count
2
9
Target Price
$6.00
$29.50
AVG Volume (30 Days)
1.7M
1.7M
Earning Date
11-05-2025
11-06-2025
Dividend Yield
1.21%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,373,244,000.00
$134,481,000.00
Revenue This Year
N/A
$64.45
Revenue Next Year
$22.56
$67.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
116.21
52 Week Low
$2.97
$9.03
52 Week High
$5.74
$28.49

Technical Indicators

Market Signals
Indicator
GSM
ZYME
Relative Strength Index (RSI) 55.53 60.22
Support Level $4.42 $24.79
Resistance Level $4.79 $27.49
Average True Range (ATR) 0.20 1.27
MACD 0.06 -0.27
Stochastic Oscillator 82.54 36.74

Price Performance

Historical Comparison
GSM
ZYME

About GSM Ferroglobe PLC

Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's business segments include North America- Silicon, North America -Silicon Alloys; Europe Manganese; Europe Silicon Metals; Europe -Silicon Alloys, South Africa Silicon Metals, South Africa-Silicon Alloys, and Other segments The primary raw materials company uses to produce its electrometallurgy products includes its coal and quartz mining operations and its silicon metal and ferroalloy production.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: